Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 56 for your search:
Drug:
pegfilgrastim
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
2006-003750-23
, LINFOTARGAM, NCT00466258
2.
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
AMLSG07-04
, NCT00151242
3.
Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
EORTC-20012
, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595
4.
Phase III Randomized Study of Doxorubicin With Versus Without Ifosfamide and Pegfilgrastim in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
EORTC-62012
, NCT00061984
5.
Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0221
, S0221, NCT00070564
6.
Phase III Randomized Study of Two Schedules of Adjuvant Chemotherapy Comprising Epirubicin, Cyclophosphamide, Methotrexate, and Fluorouracil Versus Two Schedules of Adjuvant Chemotherapy Comprising Epirubicin and Capecitabine in Patients With Completely Resected Early Stage Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
ICR-TACT2
, EU-205114, EUDRACT-2004-000066-13, MREC-04/MRE00/88, ISRCTN68068041, NCT00301925
7.
Phase III Study of Neoadjuvant and Adjuvant Cisplatin-Based Chemotherapy and/or Surgical Resection in Young Patients With Stage I-IV Adrenocortical Tumor
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 22 at diagnosis
Sponsor:
NCI
Protocol IDs:
COG-ARAR0332
, ARAR0332, NCT00304070
8.
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
IIL-DLCL04
, EudraCT number 2007-000275-42, NCT00499018
9.
Phase III Randomized Pilot Study of Adjuvant Chemotherapy Comprising Doxorubicin Hydrochloride or Epirubicin Hydrochloride and Cyclophosphamide in Older Women With Invasive Breast Carcinoma
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
70 and over
Sponsor:
Other
Protocol IDs:
UKM-CCH-ACTION
, ICR-CTSU/2006/10004-ACTION, EU-20751, EUDRACT-2005-005721, ISRCTN41708421, BIG-205, BIG 2-05, NCT00516425
10.
Various G-CSF Regimens to Prevent Infection During Chemotherapy
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2-2-6 STUDY
, ZonMw ID 80-82310-98-08006, EudraCT number 2007-005402-53, NCT00536081
11.
Phase III Randomized Study of Response-Adapted Therapy Using Fludeoxyglucose F 18-PET/CT Imaging in Patients With Newly Diagnosed Stage II-IV Hodgkin Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
CRUK-2007-006064-30
, 2007-006064-30, CRUK-07/146, NCT00678327
12.
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 to 70
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
NSABP B-46-I
, USOR 07132, NCT00887536
13.
Phase I/II Study of Epirubicin, Docetaxel, and Pegfilgrastim in Women With Locally Advanced or Inflammatory Breast Cancer (Phase I, group 1 closed to accrual as of 9/13/04 and Phase II, group 1 closed to accrual as of 5/10/06)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
Other
Protocol IDs:
CAN-NCIC-MA22
, NCT00066443, MA22
14.
Phase I/II Study of Rituximab in Combination With Blood-Brain Barrier Disruption With Mannitol, Combination Chemotherapy Comprising Methotrexate and Carboplatin, and Delayed Sodium Thiosulfate in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
OHSU-1012
, OHSU-SOL-05025-L, NCT00293475
15.
Phase I/II Study of Tipifarnib and Sequential Paclitaxel Followed By Dose-Dense Doxorubicin Hydrochloride, Cyclophosphamide, and Tipifarnib in Patients With Stage IIB-IIIC Breast Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NYCC-06-12-487
, 7868, NCT00470301
16.
Phase I/II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone Hydrochloride in Patients With Previously Treated Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-05077
, MSKCC IRB PRotocol #05-077, NCT00546377
17.
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
2007-0030
, NCT00529022
18.
Phase I/II Study of Gemcitabine Hydrochloride, Paclitaxel, Ifosfamide, and Cisplatin as Salvage Chemotherapy in Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
USCTU-UR1002-GEM-TIP
, UR1002-Gem-TIP, EU-20769, EUDRACT-2004-004804-19, NCT00551122
19.
Phase I/II Study of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Primary Refractory Lymphoid Malignancies or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PSOC-2302
, 6632, FHCRC-IR-6632, NCT00601718
20.
Phase II Study of Sequential Gemcitabine and Docetaxel in Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
SARC003
, NCT00073983, NCI-04-C-0001, AEWS0421, MAYO-79-2003
21.
Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-2903
, NCT00074282, E2903
22.
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
SD01-20010120
, NCT00050674
23.
Chemotherapy Administered Every 2 Weeks with or without Pegfilgrastim (Neulasta) in Subjects with Advanced Colon Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
20020715
, NCT00094809
24.
Phase II Study of Rituximab, Cyclophosphamide, Pegylated Doxorubicin HCl Liposome, Vincristine, and Prednisone in Older Patients With Previously Untreated Aggressive Diffuse Large B-Cell Stage II-IV Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
61 and over
Sponsor:
NCI
Protocol IDs:
MDA-CCOP-2004-0305
, 2004-0305, 6485, NCI-6485, NCT00101010
25.
Phase II Study of Dose-Intensified Induction Therapy Comprising Cyclophosphamide, Vincristine, Prednisone, and Rituximab Followed by Consolidation Therapy Comprising Rituximab and High-Dose Cyclophosphamide in Adult Patients With Newly Diagnosed Burkitt or Atypical Burkitt Lymphoma or Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
30 and over
Sponsor:
NCI
Protocol IDs:
JHOC-J0409
, JHOC-04-05-13-01, NCT00133991
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
